TaiGen Biotechnology
0
0
0
About
Overview
Steering Committee
Career
Management Team
Milestones
Board of Directors
About Us
TaiGen is a discovery-based and market-focused pharmaceutical company engaging in the development of novel therapeutics for infectious diseases and other indications with high degree of unmet medical needs.
R&D Center
Pipeline
R&D Progress
Antibiotic
Taigexyn®
Influenza Antiviral
TG-1000
HCV Antiviral
Furaprevir
Stem Cell Mobilizer
Burixafor
Research
R&D Center
TaiGen’s dedicated team of professional scientists perform cutting edge research in drug discovery to advance programs efficiently. Our pipeline of anti-infective & anti-inflammatory programs are the fruits of both internal research as well as in-licensed programs.
News
News
Investors
Investors
Financial Information
Material Information
Material Information
Shareholders' Information
Shareholders' Information
Corporate Governance
Investor FAQs
Investors
Communicating with investors, cultivating long-term investor relations and highlighting corporate’s value.
Business & Partnership
ESG
Contact Us
Home
繁中
Material Information
Material Information
All Year
2025Year
2024Year
Date
Material Information
2025-03-20
TOP
公告本公司接獲合作夥伴健康元藥業集團通知抗流感病毒新藥 Pixavir marboxil(TG-1000)已向中國大陸國家藥品監督 管理局（NMPA）遞交小兒劑型臨床試驗許可之申請（IND）
2025-03-04
本公司董事會決議不分派股利.
2025-03-04
公告本公司董事會決議 召開114年股東常會相關事宜
2025-03-04
公告本公司董事會通過113年第四季合併財報
2025-02-24
公告113年合併財務報告董事會召開日期為114年03月04日
1
2
3
4
5
Next
Home
Investors
Material Information